Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?

By Zacks Investment ResearchStock MarketsMar 25, 2018 09:40PM ET
www.investing.com/analysis/will-walgreens-wba-q2-earnings-gain-from-overall-growth-200300708
Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?
By Zacks Investment Research   |  Mar 25, 2018 09:40PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is slated to release second-quarter fiscal 2018 results before the market opens on Mar 28.

Last quarter, the company had delivered a positive earnings surprise of 0.79%. It is noteworthy that Walgreens Boots has outperformed the Zacks Consensus Estimate in three of the preceding four quarters with an average positive earnings surprise of 2.43%. Let’s take a look at how things are shaping up prior to this announcement.

Key Catalysts

Over the recent past, we have observed Walgreens Boots’ Retail Pharmacy USA division to witness comparable prescription growth and benefit from strength in retail prescription market. Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume owing to previously announced pharmacy partnerships have been driving growth in this space over the past few quarters. Moreover, rising expenditure on prescription drugs and growing demand for specialty drugs have been strengthening the retail pharmacy market.

Meanwhile, during first-quarter fiscal 2018, the company exceeded 1 billion scripts on a 30-day adjusted and rolling annual basis for the first time, touching a new milestone.

Furthermore, the company’s efforts to boost its digital capabilities have started paying off. In this regard, more than 20% of the company’s retail refill scripts were initiated through digital channels with the Walgreens' mobile app, having been downloaded in excess of 50 million times since the launch.

We are also encouraged by the increase in sales at the Retail Pharmacy International segment. Furthermore, the company has been gaining on account of the company’s strategic tie-ups, which brought more patients to its U.S. pharmacies.

Walgreens Boots Alliance, Inc. Price and EPS Surprise

Meanwhile, strong market growth in certain emerging markets drove the company’s Pharmaceutical Wholesale division’s solid performance in the first-quarter fiscal 2018. We expect these trends to get reflected in fiscal second-quarter 2018 results, as well.

The Zacks Consensus Estimate for total revenues of $31.99 billion reflects an 8.6% rise on a year-over-year basis.

Also, we are upbeat about the company expanding its global footprint with its decision to acquire 40% stake in Sinopharm Holding Guoda Drugstores Co., Ltd. (GuoDa), a subsidiary of China National Accord Medicines Corporation Ltd. On completion, this investment should provide a strong impetus to Walgreens Boots’ worldwide retail pharmacy business. Notably, Shanghai-based GuoDa is a large national pharmacy chain in China. It is the retail pharmacy platform of China National Pharmaceutical Group Corporation ("CNPGC").

Moreover, the company’s acceptance of the proposal to sell part of its investment in its Chinese wholesale partner Guangzhou Pharmaceuticals Corporation for huge cash returns buoys optimism.

We are also upbeat about Walgreens Boots’ plans to expand its existing group purchasing efforts with Express Scripts Holding Company (NASDAQ:ESRX), to ensure availability of specialty brand drugs. Since biosimilars have the potential to lower production costs, the move is considered to be a prudent and timely one.

On the flip side, Walgreens Boots’ gross margin figures continued to contract in the last reported quarter as well. Lower pharmacy margins in the U.K., reflecting the reduction in funding, led to the downside. However, the company is working tirelessly to increase efficiency and provide high quality and cost-effective pharmacy services, in order to reduce overall pharmacy cost.

Here is what our quantitative model predicts:

Walgreens Boots has the right combination of two main ingredients — a positive Earnings ESP and a Zacks Rank #3 (Hold) or higher — needed for increasing the odds of an earnings beat.

Zacks ESP: The Earnings ESP for Walgreens Boots is +2.46%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Walgreens Boots carries a Zacks Rank #2 (Buy).

The Zacks Consensus Estimate for earnings of $1.55 reflects a 13.9% rise on a year-over-year basis.

Other Stocks Worth a Look

Here are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.

Edwards Lifesciences Corporation (NYSE:EW) has an Earnings ESP of +0.07% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology, Inc. (NASDAQ:ALGN) has an Earnings ESP of +1.99% and a Zacks Rank #3.

Henry Schein (NASDAQ:HSIC) has an Earnings ESP of +2.35% and a Zacks Rank #3.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>



Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Align Technology, Inc. (ALGN): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report

Original post

Zacks Investment Research
Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?
 

Related Articles

Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email